Lilly R&D personnel changes
Executive Summary
Leader of Lilly's Zyprexa product team and clinical research fellow Alan Breier, MD, assumes Chief Medical Officer and VP-Medical position; Breier replaces Michael McDonald, MD, who is leaving Lilly. VP-Clinical Research and U.S. Regulatory Affairs and Policy Tim Franson, MD, replaces Michael Clayman, MD, as VP-Global Regulatory Affairs; Clayman moves into the new position of VP-Lilly Research Laboratories. Breier and Franson report to Steven Paul, MD, recently appointed R&D president (1"The Pink Sheet" May 19, 2003, p. 16)...